Haemonetics Q1 FY27 adjusted EPS rises 4% to $1.14; revenue climbs 5.6% to $339.4 million

Reuters2026/08/06 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Haemonetics posted Q1 fiscal 2027 GAAP net income of $33 million, down 2.94% year over year; GAAP EPS rose to $0.72 from $0.70.
GAAP revenue climbed 5.6% to $339.4 million; Apheresis increased 5.3% to $191.3 million, MedSurg rose 6% to $148.1 million.
GAAP operating income rose 6.68% to $57.5 million, while the GAAP net income margin narrowed 0.9 percentage points to 9.7%.
Non-GAAP adjusted EPS increased 3.64% to $1.14, while non-GAAP adjusted operating margin slipped 0.7 percentage points to 23.4%.
Full-year fiscal 2027 organic revenue growth outlook was raised to 4%-7%, while free cash flow conversion guidance stayed near 80%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Haemonetics Q1 FY27 adjusted EPS rises 4% to $1.14; revenue climbs 5.6% to $339.4 million

You may also like

Crypto prices